Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Shareholder Meeting (November 2022)
32 slides from Zelira Therapeutics's shareholder meeting presentation, Nov 17, 2022
Slide 1: Zelira Therapeutics AGM 17 November 2022
For personal use only ZELIRA THERAPEUTICS A Global Biopharmaceutical Company Developing and Commercialising Clinically Validated Cannabinoid-Based Medicines AGM 17 NOVEMBER 2022 ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Disclaimer & Important Notice
Disclaimer & Important Notice For personal use only Disclaimer Future Matters This presentation has been prepared by Zelira Therapeutics right to update, amend or supplement the information This presentation contains reference to certain intentions, Ltd ACN 103 782 378 (“Company”). It does not purpo
Slide 3: Global Board of Directors
Global Board of Directors For personal use only Osagie Imasogie Dr. Oludare Odumosu Lisa Gray Tim Slate Chairman Global CEO Director Non-Executive Director • Over 30 years in the field of law, finance, • Post-clinical development of • Served as COO for Glaxo Smithkline • Founder, Director of account
Slide 4: How to Vote
VOTING How to Vote For personal use only When the poll is open, select the vote icon at the top of the screen Broadcast Vote Q&A Documents Items of business 2A Re-elect Mr Sam Sample as a Director To vote, select either For, Against or Abstain FOR AGAINST ABSTAIN 2B Re-elect Mrs Jane Citizen as a Di
Slide 5: How to Ask a Question
QUESTIONS How to ask a Question For personal use only To ask a written question select the To ask a verbal question follow Q & A icon the instructions below the broadcast window. Broadcast Vote Q&A Documents Your question(s) You may enter a question using the field below Select the topic your questi
Slide 6: Chairman's Address
For personal use only Chairman’s Address CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 7: CEO & Managing Director's Address
For personal use only CEO & Managing Director’s Address CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 8: Company Overview
COMPANY OVERVIEW Zelira is a global biopharmaceutical For personal use only company researching, developing, and commercialising clinically validated cannabinoid-based medicines. It offers investors exposure to a rapidly emerging global industry at a very attractive valuation, with multiple shots on
Slide 9: Milestones achieved in 2021
Milestones achieved in 2021 202 For personal use only Levin health licensing Breakthrough Zelira® US Zelira® raises US$5 and management research at Curtin Observational million from Quincy agreement signed to University (Australia) Clinical Pain Street Capital LLC, conduct chronic pain demonstrates
Slide 10: Milestones achieved YTD in 2022
Milestones achieved YTD in 2022 For personal use only 202 Zelira®, in partnership with CVSCM launched ITURA™ Advance Relief Cream Progressed arm one (enrolment of 20 patients) of a three-arm diabetic nerve pain drug trial, a head-to-head trial against a Big Pharmaceutical company’s Zenivol® receives
Slide 11: Zelira expands into Germany with ZENIVOL
Zelira expands into Germany with ZENIVOL® For personal use only • In July 2022 Zenivol® received formal approval from German regulatory authority BfArM, for commercialisation by Adjupharm GmbH • Formal approval of Zenivol® is a major milestone in Zelira’s expansion into Germany, one of the world’s l
Slide 12: Fundraising
FUNDRAISING At a Group level, fundraising values Zelira® at For personal use only A$122.8M Milestones of US based product sales exceeded US $1 million thereby satisfying the Class A Performance US$5 million raised from Australian operations remain a rights held by Zelira directors and the original I
Slide 13: Revenue Streams
REVENUE STREAMS Clinical Trials 4 Rx For personal use only Insomnia Oral Health 2 Opioid Sparing Autism OTC Toothpaste Additional Products, 2022 Launch 3 Dermatology 5 Pharma OTC Rx 1 Launch & Learn Five acne treating Pain Rx products launched 2021 GI Autism Aged disorders Insomnia CONFIDENTIAL UNDE
Slide 14: Rapid Commercialisation Strategy
RAPID COMMERCIALISATION STRATEGY Launch For personal use only Generate proprietary formulations Launch products in global markets Rapid path to revenues Low Capex model Learn Collect real-world patient data Refine product to meet patient needs Real-time response to market Develop Patient data inform
Slide 15: Pipeline
PIPELINE Oral Care Autism Insomnia For personal use only Dermatology Targeted Aged Product SprinJene HOPE® Zenivol® RAF FIVE™ Pain Disorder CBD IRB approved Launched Launched Launched Launched Launched Launched observational 2020 2020 2021 2021 2021 2022 Status clinical study Current Markets Next St
Slide 16: HOPE for autism spectrum disorder overview
Overview HOPE® for behaviours For personal use only Two published, longitudinal real world data studies associated with Autism demonstrated improvements in autism related behaviours Spectrum Disorder and quality of life for patient and carers with HOPE® Rx US Revenues: Licensed in Louisiana and Wash
Slide 17: HOPE longitudinal, real-world data study
Zelira sponsored – HOPE® longitudinal, real-world data study For personal use only Clinical Global Impression (CGI) Global Improvement and Efficacy scores of Emerald HOPE® patients CGI Global Improvement 100% % of patients as rated by the clinician 80% Improvements in CGI Global were 60% observed wi
Slide 18: Zenivol for chronic insomnia overview
Overview Zenivol® for chronic, For personal use only • World’s first clinically validated cannabinoid drug for chronic insomnia unresolved insomnia • Phase 1B/2A clinical trial confirmed Zenivol® safe, efficacious and improved quality of life Rx • Significant reduction in insomnia symptoms • Clinica
Slide 19: ZENIVOL longitudinal, real-world data study
Zelira sponsored – ZENIVOL® longitudinal, real-world data study For personal use only Change in Insomnia status whilst on ZENIVOL®, as measured by the Insomnia Severity Index (ISI) Insomnia status at follow up (% of patients) 100% 90% 80% 70% Overall, patients taking 60% ZENIVOL® improved 50% from a
Slide 20: Oral Care – SprinJene CBD
Overview Oral Care – SprinJene CBD For personal use only • Full line of CBD oral care products OTC Toothpaste was launched in Q1 2021 and generating revenue with strong growth potential Available for purchase on zeliraoralcare.com, sprinjenecbd.com, amazon.com and wholesale distribution channels in
Slide 21: RAF FIVE - Differentiated dermatology
RAF FIVE™ - Differentiated dermatology Overview For personal use only • Science-backed Platform Technology OTC • Focus on significant unmet needs in Dermatology Dr. Karyn Grossman in the News • Innovative Branding and Market–ready products • World Class Inventors and Formulators Zylorma™, a propriet
Slide 22: RAF FIVE Product Range
RAF FIVE™ Product Range For personal use only WASH AWAY GEL CLEANSER ACNE TREATMENT SPOT ON ACNE TREATMENT KICK OFF HYDRATING LOTION BROAD SPECTRUM SPF 30 SUNSCREEN AFTER HOURS MOISTURIZING LOTION ACNE TREATMENT CLEAR THE WAY ACNE TREATMENT PADS CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 23: Enhanced Distillate Capture and Dissolution Matrix (EDCDM)
Enhanced Distillate Capture and Dissolution Matrix (EDCDM) For personal use only DIFFICULTY WITH FORMULATION AND DEVELOPMENTS OF FREE FLOW Distillate into capsules CANNABINOID POWDER-BASED CAPSULES AND TABLETS DUE TO NON-UNIFORMITY and tablets, made easy PROBLEM DISTILLATE AND SEPARATING FROM POWDER
Slide 24: Zelira Patent Portfolio
Zelira Patent Portfolio For personal use only Going into 2022-23 Zelira’s patent portfolio has been granted or under consideration in 26 countries spanning across the globe. There are 41 patents granted and 100 under prosecution across 9 different therapeutic areas Therapeutic Area Granted/Allowed U
Slide 25: Corporate Snapshot
Corporate Snapshot For personal use only Financials (as at 11 November 2022) Share Price (Market Data as at 11 November 2022) AUD$ Share Price 1.04 52w Range 0.97 - 7.54 Market Capitalisation 10M Cash (at 30 Sept 2022) 1.2M Capital Structure (Fully Diluted2) Structure Major Shareholders Directors Ho
Slide 26: Formal Business
For personal use only Formal Business CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 27: AGM Resolutions: Adoption of Remuneration Report
AGM RESOLUTIONS For personal use only Resolution 1 Adoption of Remuneration Report To consider and, if thought fit, to pass, with or without amendment, the following as an non-binding resolution: That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval i
Slide 28: AGM Resolutions: Election of Director – Tim Slate
AGM RESOLUTIONS For personal use only Resolution 2 Election of Director – Tim Slate To consider and, if thought fit, to pass, with or without amendment, the following as an ordinary resolution: That, for the purpose of clause 12.7 of the Constitution, ASX Listing Rule 14.4 and for all other purposes
Slide 29: AGM Resolutions: Approval of 10% Placement Capacity
AGM RESOLUTIONS For personal use only Resolution 3 Approval Of 10% Placement Capacity To consider and, if thought fit, to pass, with or without amendment, the following as an special resolution: That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company
Slide 30: AGM Resolutions: Adoption of Incentive Plan
AGM RESOLUTIONS For personal use only Resolution 4 Adoption of Incentive Plan To consider and, if thought fit, to pass, with or without amendment, the following as an ordinary resolution: That, for the purposes of ASX Listing Rule 7.2 (Exception 13(b)) and for all other purposes, approval is given f
Slide 31: AGM Resolutions: Replacement of Constitution
AGM RESOLUTIONS For personal use only Resolution 5 Replacement of Constitution To consider and, if thought fit, to pass, with or without amendment, the following as an special resolution: That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given f
Slide 32: Thank You
For personal use only Thank You Zelira Therapeutics Phone +1-484-630-0650 | Email info@zeliratx.com zeliratx.com
Zelira Therapeutics — Shareholder Meeting (November 2022) on 6ix